Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Jack Allen - Baird Operator Welcome to the Fate Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investors secti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdiction of incorp ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Mara Goldstein - Mizuho Daina Graybosch - SVB Securities Andrea Tan - Goldman Sachs Matthew Biegler - Oppenheimer Operator Welcome to the Fate Therapeutics Firs ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 12278 Scripps Summit Drive, San Diego, CA 92131 (Address of principal executive offices) (Zip Code) ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medical Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Carly Kenselaar - Citi Daina Graybosch - SVB Securities Tazeen Ahmad - Bank of America Andrea Tan - Goldman Sachs Robyn Karnauskas - Truist Mara Goldstein - Mizuho Matthew Biegler - Opp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Better Cells For Better Therapies™ | --- | --- | |----------------------------------------------------------------------------------------------------------------------|-------| | | | | Programmed Cellular Immunotherapies | | | Transforming the Treatment of Cancer with Off-the-shelf, Multiplexed-engineered, iPSC-derived Cellular Immunotherapy | | | November 2022 | | - Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Re ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Michael Yee - Jefferies Tyler Van Buren - Cowen Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Securities Daina Graybosch - SVB Securities Peter Lawson - Barclays Gil Blum - Needham ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 (Exact name o ...

Fate Therapeutics Inc. (NASDAQ:FATE) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Kelsey Goodwin - Guggenheim Securities Tyler Van Buren - Cowen Ashiq Mubarack - Citigroup Michael Yee - Jefferies James Shin - Abbott Matt Biegler - Oppenheimer Daina Graybosch - SVB Securities Robyn Kay Karnauskas - Truist Securities Operator Welcom ...